tradingkey.logo

Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score

ReutersMar 1, 2026 2:47 PM

- Upstream Bio Inc UPB.O:

  • UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AT 2026 AAAAI ANNUAL MEETING

  • UPSTREAM BIO INC - PRIMARY ENDPOINT SHOWED REDUCTION OF -1.95 IN NASAL POLYP SCORE

  • UPSTREAM BIO INC - SECONDARY ENDPOINTS SHOWED REDUCTION IN NASAL CONGESTION SCORE BY -0.96

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI